Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2015 Sep 2;14(11):2519–2526. doi: 10.1158/1535-7163.MCT-15-0383

Figure 3.

Figure 3

A: Two representative cell lines were treated with neratinib 0.01 µM, taselisib 0.01 µM and the combination of both (neratinib 0.01 µM and taselisib 0.01 µM) collected 24 hours and 48 h (B) after treatment. Cells were used for Western blotting analyses of phosphorylated HER2, EGFR, AKT and S6. Neratinib was able to reduce levels of p-HER2 and p-EGFR in both cell lines tested. Combination treatment led to reduced levels of p-AKT and p-S6 in USPC-ARK-1 cells, while a decrease in p-S6 but not p-AKT was found in combination-treated USPC-ARK-2 cells. Expression of GAPDH was used as loading control. C: USPC-ARK-1 single agent resistant cell lines. Two weeks exposure to neratinib induced significant increase in phosphorylated AKT, while two weeks exposure to taselisib induced a significant increase phosphorylated HER2, EGFR and ERK.